AllBright Advised Ceva, a French Company, in Completing the Acquisition of a Well-Known Animal Vaccine Manufacturer in China2017-03-013588
On February 22, 2017, a global animal healthcare and animal vaccine company headquartered in France which is ranked among the top 6 companies globally, announced that it has successfully completed the acquisition of 64% equity interest of Zhejiang EBVAC Biotech Co., Ltd.. As from the closing date, Zhejiang EBVAC Biotech Co., Ltd. has renamed into Zhejiang Ceva Ebvac Biotech Co., Ltd. and restructured into a Sino-foreign joint venture enterprise jointly owned by Ceva, China Animal Health and Epidemiology Center and Qingdao Yebio Biological Engineering Co., Ltd. This transaction will further strengthen the leading position of Ceva in global animal vaccine market.
As one of the important cooperation projects between China and French enterprises, Ceva, China Animal Health and Epidemiology Center and Qingdao Yebio Biological Engineering Co., Ltd. jointly signed the document in respect of the post-acquisition cooperation on February 21, 2017 in the presence of the Chinese Prime Minister Li Keqiang and French Prime Minister Bernard Cazeneuve.
AllBright team, including Senior Partner Dr. Philip Zhang, and associates Tony Zhang and Bianca Han, has acted as the legal counsel of Ceva in this transaction, and provided a full range of legal services including, among others, preparing memorandum of understanding, conducting legal due diligence, proposing deal structure, drafting bilingual transaction documents, and participating in all rounds of business negotiations and closing process.